Brought to you by 
BMS signs large-molecule licensing agreement with Ambrx
28 Aug 2019
Executive Summary
Ambrx Inc. (protein therapeutics and antibody-drug conjugates) has licensed Bristol-Myers Squibb Co. exclusive global rights to research, develop, and market modified forms of fibroblast growth Factor 21 (FGF-21) for Type II diabetes, and relaxin for heart failure, both currently in preclinical. NOTE: The FGF-21 therapeutic, also known as BMS986036, is also being tested in liver fat, liver injury, and fibrosis in nonalcoholic steatohepatitis patients.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS signs large-molecule licensing agreement with Ambrx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice